Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.83
- Piotroski Score 3.00
- Grade Buy
- Symbol (PHAR)
- Company Pharming Group N.V.
- Price $8.49
- Changes Percentage (3.79%)
- Change $0.31
- Day Low $8.25
- Day High $8.49
- Year High $13.20
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.16
- Trailing P/E Ratio -52.75
- Forward P/E Ratio -52.75
- P/E Growth -52.75
- Net Income $-10,548,000
Income Statement
Quarterly
Annual
Latest News of PHAR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China
LEO Pharma has submitted an NDA in China for Enstilar, a new treatment for plaque psoriasis. Enstilar aims to improve upon the existing standard treatment, Daivobet ointment....
By Yahoo! Finance | 1 day ago -
Could Amazon Pharmacy Become the Largest Drug Store in the USA?
Amazon has quietly entered the healthcare market, particularly in prescription drugs. With the launch of Amazon Pharmacy, offering discounts and convenience, it aims to revolutionize the sector. The c...
By Forbes | 1 day ago -
Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
The recent interest rate cut by the U.S. Federal Reserve has boosted investor sentiment and market outlook. With stocks rallying, the focus shifts to stocks at 52-week lows, presenting potential buyin...
By Yahoo! Finance | 1 day ago